Nokea
A patient wants to know about the possible interactions of the various drugs that he has been prescribed for an illness. The nurse explains that the drugs interact with each other and produce an effect that is greater than the sum of their separate actions. Which of the following reactions is the nurse informing about?
- A. Additive drug reaction
- B. Synergistic drug reaction
- C. Antagonistic drug reaction
- D. Toxic drug reaction
Correct Answer: B
Rationale: A synergistic drug reaction occurs when drugs interact with each other and produce a sum greater than the sum of their separate actions. An additive drug reaction occurs when the combined effect of two drugs is equal to the sum of each drug given alone. An antagonistic drug reaction occurs when one drug interferes with the action of another, causing neutralization or a decrease in the effect of one drug. Toxic drug reactions are caused when blood concentration levels exceed the therapeutic levels of a drug.
You may also like to solve these questions
A nursing student is reviewing information about the Controlled Substances Act of 1970. The student would expect to find which of the following as being regulated for drugs classified as controlled substances? Select all that apply.
- A. Manufacturing
- B. Elimination
- C. Distribution
- D. Formulation
- E. Dispensing
Correct Answer: A,C,E
Rationale: The Controlled Substances Act of 1970 regulates the manufacture, distribution, and dispensing of drugs classified as controlled substances. Elimination refers to the excretion of drugs from the body, a pharmacokinetic activity. The act does not address formulation of the drug.
After teaching a group of nursing students about pharmacokinetics, the instructor determines that the teaching was successful when the students identify which of the following as a phase? Select all that apply.
- A. Absorption
- B. Distribution
- C. Administration
- D. Metabolism
- E. Excretion
Correct Answer: A,B,D,E
Rationale: The pharmacokinetic phases are absorption, distribution, metabolism, and excretion. The acronym ADME is a helpful way to remember the pharmacokinetic phases.
After teaching a group of nursing students about the half-life of a drug, the instructor determines the need for additional teaching when the students identify which of the following as true? Select all that apply.
- A. Half-life can be decreased in clients with renal disease.
- B. Half-life can help determine dosing frequency.
- C. Half-life does not change throughout a client's life.
- D. Layer disease can increase half-life.
- E. Half-life is the measure of the rate at which drugs are removed from the body.
Correct Answer: A,C
Rationale: Half-life is the measure of the rate at which drugs are removed from the body, and any difficulty in excreting a drug increases half-life, including liver or kidney disease or advanced age.
Which of the following names may be assigned to a drug during the process of development? Select all that apply.
- A. Chemical name
- B. Official name
- C. Pharmacologic name
- D. Trade name
- E. Nonproprietary name
Correct Answer: A,B,D,E
Rationale: Throughout the process of development, drugs may have several names assigned to them including a chemical name, a generic (nonproprietary) name, an official name, and a trade or brand name.
When reviewing the phases of drug development, the nurse finds a discussion about the postmarketing surveillance phase. Which one of the following activities would the nurse expect to find as being carried out during this phase?
- A. Health care providers report adverse effects to FDA.
- B. Healthy volunteers are involved in the test.
- C. In vitro tests are performed using human cells.
- D. The drug is given to patients with the disease.
Correct Answer: A
Rationale: The postmarketing surveillance phase of drug development encourages health care professionals to report adverse effects of drugs to the FDA using MedWatch. Phase 1 of clinical testing involves 20 to 100 healthy volunteers. In vitro testing of the drug on human or animal cells is done in the pre-FDA phase. In Phase 2 of clinical testing, the drug is given to patients with the disease for which the drug is manufactured.